VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Search Videos by Topic or Participant
Browse by Series:

Ramucirumab in Metastatic NSCLC

Panelists: Roy S. Herbst, MD, PhD, Yale; Mark A. Socinski, MD, University of Pittsburgh;Thomas E. Stinchcombe, MD, UNC; Anne S. Tsao, MD, MD Ande
Published: Monday, May 25, 2015
For High-Definition, Click
Ramucirumab is a fully human monoclonal antibody directed against VEGFR-2 that works on the receptor of endothelial cells as well as tumor cells, explains Roy S. Herbst, MD, PhD. Ramucirumab was approved by the FDA in December 2014 for the treatment of patients with metastatic non-small cell lung cancer (NSCLC), based on the phase III REVEL trial.

In the international study, 1253 patients with nonsquamous and squamous cell NSCLC received either ramucirumab plus docetaxel or placebo plus docetaxel. Patients in the study had experienced disease progression after treatment with platinum-based chemotherapy for locally advanced or metastatic disease.

Median overall survival with ramucirumab was superior compared with placebo (10.5 vs 9.1 months; hazard ratio [HR], 0.857; P = .0235), as was median progression-free survival (4.5 vs 3.0 months; HR, 0.762; P < .0001). The overall response rate was also significantly better with ramucirumab (23% vs 14%; P < .0001). Although there were concerns about toxicity profile, particularly in patients with squamous cell disease, ramucirumab did not produce a significantly higher rate of severe adverse events.
Slider Left
Slider Right
For High-Definition, Click
Ramucirumab is a fully human monoclonal antibody directed against VEGFR-2 that works on the receptor of endothelial cells as well as tumor cells, explains Roy S. Herbst, MD, PhD. Ramucirumab was approved by the FDA in December 2014 for the treatment of patients with metastatic non-small cell lung cancer (NSCLC), based on the phase III REVEL trial.

In the international study, 1253 patients with nonsquamous and squamous cell NSCLC received either ramucirumab plus docetaxel or placebo plus docetaxel. Patients in the study had experienced disease progression after treatment with platinum-based chemotherapy for locally advanced or metastatic disease.

Median overall survival with ramucirumab was superior compared with placebo (10.5 vs 9.1 months; hazard ratio [HR], 0.857; P = .0235), as was median progression-free survival (4.5 vs 3.0 months; HR, 0.762; P < .0001). The overall response rate was also significantly better with ramucirumab (23% vs 14%; P < .0001). Although there were concerns about toxicity profile, particularly in patients with squamous cell disease, ramucirumab did not produce a significantly higher rate of severe adverse events.
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Updates in Novel Therapeutic Options for Lung Neuroendocrine TumorsMay 31, 20181.0
Community Practice Connections™: Working Group to Optimize Outcomes in EGFR-mutated Lung Cancers: Evolving Concepts for Nurses to Facilitate and Improve Patient CareJun 30, 20181.5
Publication Bottom Border
Border Publication
x